Antiparkinsonian effects of aqueous methanolic extract of hyoscyamus niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency

Neurochemical Research

Volumn 36, Issue 1, 2011, Pages 177-186

  Sengupta, T ^a   Vinayagam, J ^a   Nagashayana, N ^b   Gowda, B ^c   Jaisankar, P ^a   Mohanakumar, K P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b GOVERNMENT OF INDIA   (India)

^c UNIVERSITY OF AGRICULTURAL SCIENCES   (India)

Author keywords

Akinesia; Anti parkinsonian activity; Antioxidant; Ayurveda; Catalepsy; Hydroxyl radical; MAO B inhibitor; Swim score

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIPARKINSON AGENT; DOPAMINE; HYDROXYL RADICAL; HYOSCYAMUS NIGER EXTRACT; METHANOL; PLANT EXTRACT; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPARKINSONIAN ACTIVITY; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; ELECTROCHEMISTRY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MITOCHONDRION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PLANT SEED; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYL RADICAL; HYOSCYAMUS; MALE; MEDICINE, AYURVEDIC; METHANOL; MICE; MICE, INBRED BALB C; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MPTP POISONING; PARKINSON DISEASE; PLANT EXTRACTS;

GUIZOTIA ABYSSINICA; HYOSCYAMUS; HYOSCYAMUS NIGER; MUS; PARKINSONIA;

EID: 78651310766     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0289-x     Document Type: Article

References (52)

1. M Sawant JC Isaac S Narayanan 2004 Analgesic studies on total alkaloids and alcohol extracts of Eclipta alba (Linn.) Hassk Phytotheyapt Res 18 111 113 1:CAS:528:DC%2BD2cXjtFCrtbc%3D 10.1002/ptr.1165 (Pubitemid 38380602)
2. N El Jaber-Vazdekis C González AG Ravelo, et al. 2009 Cloning, characterization and analysis of expression profiles of a cDNA encoding a hyoscyamine 6-beta-hydroxylase (H6H) from Atropa baetica Willk Plant Physiol Biochem 47 20 25 1:CAS:528:DC%2BD1cXhsFamtbnI 10.1016/j.plaphy.2008.09.004 18952449
3. 2+ channels Fundam Clin Pharmacol 22 87 99 1:CAS:528:DC%2BD1cXis12kt7w%3D 10.1111/j.1472-8206.2007.00561.x 18251725 (Pubitemid 351171292)
4. IA Ramoutsaki CE Papadakis IA Ramoutsakis, et al. 2002 Therapeutic methods used for otolaryngological problems during the Byzantine period Ann Otol Rhinol Laryngol 111 553 557 12090712
5. CY Ma WK Liu CT Che 2002 Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds J Nat Prod 65 206 209 1:CAS:528:DC%2BD38XlsVGntQ%3D%3D 10.1021/np010073b 11858758 (Pubitemid 34171184)
6. M Gouriedevi MG Ramu BS Venkararam 1991 Treatment of Parkinson's disease in 'Ayurveda' (ancient Indian system of Medicine): discussion paper J R Soc Med 84 491 492 1:STN:280:DyaK3MzlvFaqsw%3D%3D
7. N Nagashayana P Sankarankutty MR Nampoothiri, et al. 2000 Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease J Neurol Sci 176 124 127 1:CAS:528:DC%2BD3cXltlWhtr0%3D 10.1016/S0022-510X(00) 00329-4 10930594 (Pubitemid 30621609)
8. HM Reza H Mohammad E Golnaz, et al. 2009 Effect of methanolic extract of Hyoscyamus reticulatus L. on the seizure induced by picritoxin in mice Pak J Pharmacol Sci 22 308 312
9. AU Khan AH Gilani 2008 Cardiovascular inhibitory effects of Hyoscyamus reticulatus Methods Find Exp Clin Pharmacol 30 295 300 1:CAS:528: DC%2BD1cXhtFKntLfM 10.1358/mf.2008.30.4.1186075 18773124
10. R Katzenschlager A Evans A Manson, et al. 2004 Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study J Neurol Neurosurg Psychiatry 75 1672 1677 1:STN:280:DC%2BD2crnvFOntw%3D%3D 10.1136/jnnp.2003.028761 15548480 (Pubitemid 39611463)
11. BV Manyam M Dhanasekaran TA Hare 2004 Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters Phytotherapy Res 18 97 101 10.1002/ptr.1407 (Pubitemid 38380599)
12. SR Sankar T Manivasagam V Sankar, et al. 2009 Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse J Ethnopharmacol 125 369 373 10.1016/j.jep.2009.08.003 19666100
13. SR Sankar T Manivasagam A Krishnamurti, et al. 2007 The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables Cell Mol Biol Lett 12 473 481 1:CAS:528:DC%2BD2sXht1GqsLfE 10.2478/s11658-007-0015-0 17415533
14. M Ahmad S Saleem AS Ahmad, et al. 2005 Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats Hum Exp Toxicol 24 137 147 10.1191/0960327105ht509oa 15901053 (Pubitemid 40605154)
15. N Mitra KP Mohanakumar DK Ganguly 1994 Resistance of golden hamster to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase-B J Neurochem 62 1906 1912 1:CAS:528: DyaK2cXivFWlurY%3D 10.1046/j.1471-4159.1994.62051906.x 8158138
16. M Sedelis K Hofele GW Auburger S Morgan JP Huston RK Schwarting 2000 Evidence for resistance to MPTP in C57BL/6 × BALB/c F1 hybrids as compared with their progenitor strains Neuroreport 11 1093 1096 1:CAS:528: DC%2BD3cXivFOgtr4%3D 10.1097/00001756-200004070-00037 10790888
17. NM Filipov AB Norwood SC Sistrunk 2009 Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent Neuroreport 20 713 717 1:CAS:528:DC%2BD1MXltV2hsrc%3D 10.1097/WNR.0b013e32832aa95b 19349914
18. JA Hoskins LJ Davis 1989 The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice Neuropharmacology 28 1389 1397 1:CAS:528:DyaK3cXltVantA%3D%3D 10.1016/0028-3908(89)90015-4 2615917 (Pubitemid 20008276)
19. LG Chia SP Liu EH Lee 1992 Differential effects of deprenyl and MPTP on catecholamines and activity in BALB/c mice Neuroreport 3 777 780 1:CAS:528:DyaK3sXhs1Omtw%3D%3D 10.1097/00001756-199209000-00014 1421136
20. S Samantaray KP Mohanakumar 2003 Calcium channel agonist, (±)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in Balb/c mice Neurosci Lett 346 69 72 1:CAS:528:DC%2BD3sXltF2gtrc%3D 10.1016/S0304-3940(03)00577-9 12850550 (Pubitemid 36792195)
21. R Haobam KM Sindhu G Chandra KP Mohanakumar 2005 Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains Behav Brain Res 163 159 167 1:CAS:528:DC%2BD2MXns1WjsLY%3D 10.1016/j.bbr.2005.04.011 15941598 (Pubitemid 41138049)
22. N Mitra KP Mohanakumar DK Ganguly 1992 Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice Brain Res Bull 28 355 364 1:CAS:528: DyaK38XisFSjt7Y%3D 10.1016/0361-9230(92)90035-V 1350496
23. D Muralikrishnan KP Mohanakumar 1998 Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in mice FASEB J 12 905 912 1:CAS:528:DyaK1cXktlCrsro%3D 9657530
24. KP Mohanakumar D Muralikrishnan B Thomas 2000 Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity Brain Res 864 281 290 1:CAS:528:DC%2BD3cXivVGgs7g%3D 10.1016/S0006-8993(00)02189-2 10802035 (Pubitemid 30235109)
25. A Morinan HM Garratt 1985 An improved fluorimetric assay for brain monoamine oxidase J Pharmacol Methods 13 213 223 1:CAS:528:DyaL2MXktlersbY%3D 10.1016/0160-5402(85)90021-X 3923270 (Pubitemid 15003291)
26. OH Lowry NJ Rosebrough AL Farr, et al. 1951 Protein measurement with the Folin phenol reagent J Biol Chem 193 265 275 1:CAS:528:DyaG38XhsVyrsw%3D%3D 14907713
27. KP Mohanakumar A de Bartolomeis RM Wu, et al. 1994 Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation Ann N Y Acad Sci 738 392 399 1:CAS:528:DyaK28XjvV2ksL0%3D 10.1111/j.1749-6632.1994.tb21828.x 7832447
28. R Banerjee KS Saravanan B Thomas, et al. 2008 Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats Neurochem Res 33 985 995 1:CAS:528:DC%2BD1cXks1Ggu70%3D 10.1007/s11064-007-9473-z 17763941
29. B Thomas KS Saravanan KP Mohanakumar 2008 In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole Neurochem Int 52 990 1001 1:CAS:528:DC%2BD1cXktVKlu78%3D 10.1016/j.neuint.2007.10.012 18164516
30. AK Navneet TA Appukuttan M Pandey 2008 Taurine fails to protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion in mice Amino Acids 35 457 461 1:CAS:528:DC%2BD1cXpvVKgtrk%3D 10.1007/s00726-007-0571-7 17701098
31. B Halliwell H Kaur M Ingelman-Sundberg 1991 Hydroxylation of salicylate as an assay for hydroxyl radiocals: a cautionary note Free Radic Biol Med 10 439 441 1:CAS:528:DyaK38XivFOr 10.1016/0891-5849(91)90052-5 1654291
32. CY Ma ID William CT Che 1999 Withanolides from Hyoscyamus niger seeds J Nat Prod 62 1445 1447 1:CAS:528:DyaK1MXls1Kqu7k%3D 10.1021/np9902082 10543915 (Pubitemid 29504117)
33. B Sajeli M Sahai R Suessmuth, et al. 2006 Hyosgerin, a new optically active coumarinolignan, from the seeds of Hyoscyamus niger Chem Pharm Bull 54 538 541 1:CAS:528:DC%2BD28XkslOhtrw%3D 10.1248/cpb.54.538 16595960
34. AS Begum S Verma M Sahai, et al. 2009 Hyoscyamal, a new tetrahydrofurano lignan from Hyoscyamus niger Linn Nat Prod Res 23 595 600 1:CAS:528: DC%2BD1MXmvVagsb0%3D 10.1080/14786410802113961 19401911
35. Brown JH, Taylor P (2001) Muscarinic receptors agonist and antagonists. In: Hardman JG, Limbird LE, Gilman's AG (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, p 10
36. M Asahina H Shinotoh K Hirayama, et al. 1995 Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET Acta Neurol Scand 91 437 443 1:STN:280:DyaK28%2Fht1entg%3D%3D 10.1111/j.1600-0404.1995. tb00443.x 7572037
37. M Quik 2004 Smoking, nicotine and Parkinson's disease Trends Neurosci 27 561 568 1:CAS:528:DC%2BD2cXntFCjtbw%3D 10.1016/j.tins.2004.06.008 15331239 (Pubitemid 39149826)
38. R Rodriguez-Puertas A Pazos J Pascual 1994 Cholinergic markers in degenerative parkinsonism: autoradiographic demonstration of high-affinity choline uptake carrier hyperactivity Brain Res 636 327 332 1:CAS:528: DyaK2cXhs1Sltrw%3D 10.1016/0006-8993(94)91032-4 8012816 (Pubitemid 24044650)
39. AH Schapira E Bezard J Brotchie, et al. 2006 Novel pharmacological targets for the treatment of Parkinson's disease Nat Rev Drug Discov 5 845 854 1:CAS:528:DC%2BD28XhtVajsbnE 10.1038/nrd2087 17016425 (Pubitemid 44480538)
40. OM Abdel-Salam 2008 Drugs used to treat Parkinson's disease, present status and future directions CNS Neurol Disord Drug Targets 7 321 342 1:CAS:528:DC%2BD1MXmt1egug%3D%3D 10.2174/187152708786441867 18991661
41. RL Rodnitzky 1999 Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 57 845 849 1:CAS:528:DyaK1MXkt1Gns7Y%3D 10.2165/00003495-199957060-00001 10400399 (Pubitemid 29313195)
42. S Mandel E Grünblatt P Riederer, et al. 2003 Neuroprotective strategies in Parkinson's disease: an update on progress CNS Drugs 17 729 762 1:CAS:528:DC%2BD3sXntl2nsLk%3D 10.2165/00023210-200317100-00004 12873156 (Pubitemid 37000010)
43. + toxicity by deprenyl (selegiline) Ann N Y Acad Sci 738 214 221 1:CAS:528:DyaK28XjvV2ksr8%3D 10.1111/j.1749-6632.1994.tb21806.x 7832430
44. B Thomas D Muralikrishnan KP Mohanakumar 2000 In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice Brain Res 852 221 224 1:CAS:528:DC%2BD3cXnt1Kksw%3D%3D 10.1016/S0006-8993(99)02202-7 10661517 (Pubitemid 30017755)
45. K Sairam KS Saravanan R Banerjee, et al. 2003 Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats Brain Res 966 245 252 1:CAS:528:DC%2BD3sXhs1ags7Y%3D 10.1016/S0006-8993(02)04174-4 12618347 (Pubitemid 36255587)
46. KP Mohanakumar B Thomas SM Sharma, et al. 2002 Nitric oxide: an antioxidant and neuroprotector Ann N Y Acad Sci 962 389 401 1:CAS:528: DC%2BD38XltFalur8%3D 10.1111/j.1749-6632.2002.tb04083.x 12076990
47. D Muralikrishnan S Samantaray KP Mohanakumar 2003 D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- induced dopaminergic neurotoxicity Synapse 50 7 13 1:CAS:528: DC%2BD3sXmvVChurk%3D 10.1002/syn.10239 12872288 (Pubitemid 37034108)
48. B Thomas KP Mohanakumar 2004 Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the mouse nigrostriatum J Pineal Res 36 25 32 1:CAS:528:DC%2BD2cXotFKksg%3D%3D 10.1046/j.1600-079X.2003.00096.x 14675127 (Pubitemid 38130286)
49. DS Maharaj KS Saravanan H Maharaj, et al. 2004 Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats Neurochem Int 44 355 360 1:CAS:528:DC%2BD3sXpt1Squrg%3D 10.1016/S0197-0186(03) 00170-0 14643753 (Pubitemid 37485867)
50. VH Knaryan S Samantaray AA Galoyan 2005 A synthetic human proline-rich-polypeptide enhances hydroxyl radical generation and fails to protect dopaminergic neurons against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced toxicity in mice Neurosci Lett 375 187 191 1:CAS:528:DC%2BD2MXptlGnsg%3D%3D 10.1016/j.neulet.2004.11.010 15694258 (Pubitemid 40202950)
51. S Ghosal B Rama PS Chauhan R Mehta 1975 Alkaloids of Sida cordifolia Phytochemistry 14 830 832 1:CAS:528:DyaE2MXkvFert7o%3D 10.1016/0031-9422(75) 83057-3
52. T Sengupta KP Mohanakumar 2010 2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice Neurochem Int 57 637 646 1:CAS:528:DC%2BC3cXht1Wju7zL 10.1016/j.neuint.2010.07.013 20691235